All News

2018

November

Media Release / Nov 08, 2018

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Read More
Media Release / Nov 02, 2018

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs

Read More

October

Media Release / Oct 31, 2018

Sandoz receives US FDA approval for biosimilar Hyrimoz™ (adalimumab-adaz)

Read More
Media Release / Oct 23, 2018

Sandoz delivers positive results for proposed biosimilars adalimumab and etanercept

Read More
Media Release / Oct 08, 2018

Sandoz Healthcare Access Challenge (HACk) launches in US, seeking digital solutions to local healthcare access challenges

Read More

September

Media Release / Sep 27, 2018

Sandoz Inc. announces US FDA approval of pediatric dose of SYMJEPI™ (epinephrine)

Read More
Media Release / Sep 06, 2018

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

Read More

July

Media Release / Jul 06, 2018

Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance

Read More
Media Release / Jul 01, 2018

Sandoz Inc. enters exclusive agreement to distribute and commercialize SYMJEPI™ (epinephrine) in the US

Read More

April

Media Release / Apr 18, 2018

Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

Read More